Bryan Hull’s Post

In this exclusive interview, we have a special guest, Dr. Reggie Ewesuedo, Vice President of Clinical Development at Lantern Pharma Inc. (Nasdaq: LTRN), to discuss 'Breakthrough in #LungCancer Treatment for Never Smokers' including the novel #AI-assisted drug candidate #LP300. We'll dive into the promising results of the #HARMONIC Phase 2 trial, focusing on LP-300 and its significant implications for treating #lung #cancer. Additionally, we’ll explore the transformative role of #artificialintelligence in #drugdiscovery, particularly how it's reshaping #clinicaltrials and treatment strategies. https://lnkd.in/dVbpWEmm

Are you attending the Immuno by Oxford Global Conference (Immuno 2024) starting on Thursday in #London? Don’t miss out on the presentation by our VP Preclinical Research & Translation Strategy, Thorsten Ross , on April 26. He will speak about the role of GDF-15 in #cancer therapy resistance and how blocking GDF-15 can boost current standard-of-care and emerging treatments & improve #patient outcomes. The talk includes recent insights about our lead candidate visugromab, a first-in-class GDF-15-neutralizing antibody, currently being evaluated in Phase 2 clinical trials.   Download the full conference program here https://bit.ly/3UhM5I6 & learn more about our novel approach to tackling cancer resistance at www.catalym.com   #OGImmuno #Immuno24

Molecules of the Month - Dec. ‘23 | https://lnkd.in/gFiiSk86 Catch up on molecules you may have missed over the holidays! December 2023 was a big month for estrogen receptor (ER) degraders with stories from multiple Phase III candidates to treat breast cancer, including from AstraZeneca and Arvinas. In unfortunate news, Phase II trials of Boehringer Ingelheim's ENaC inhibitor to treat CF and Phase III trials of EMD Serono, Inc.'s much anticipated BTK inhibitor to treat MS were both terminated. Follow the link below to see our top molecules of December and stay tuned for Drug Hunter case studies on all the molecules featured. Full article: https://lnkd.in/gFiiSk86

👩⚕️ One of the biggest challenges in oncology is resistance. 1 in 2 people will be diagnosed with cancer in their lifetime, and over 90 % of cancer deaths are caused by drug resistance, one of the biggest unmet medical needs in the field of cancer. 👨⚕️   🎯 At Heidelberg Pharma AG the patient is the focus of all our efforts! Our amanitin-based ADC pipeline is designed to overcome resistance. 🎯 📌 Learn more about our patient-focused approach by watching our R&D webinar: https://lnkd.in/eVJygzyn   #ADCs #ATAC #CancerResearch

📰 #NSCLC | ASCO24: J&J's subQ Rybrevant matches efficacy, shrinks infusion time in Phase III trial "The PALOMA-3 trial, presented Friday at the American Society of Clinical Oncology (ASCO) annual meeting, is testing the SC formulation of J&J's EGFR/MET-targeting bispecific antibody in 418 patients with EGFR-mutated, advanced or metastatic non-small-cell lung cancer (NSCLC) and exon 19 deletion or L858R mutations [...]" https://hubs.ly/Q02zY4Bq0 FirstWord Pharma

Want to count cells like Iovance Biotherapeutics, Inc.? Use a NucleoCounter® An exciting cancer immunotherapy study by Iovance Biotherapeutics, Inc. https://okt.to/eaxfqX showed that their Gen 2 tumor-infiltrating lymphocyte (TIL) manufacturing process produces effective drug products for adoptive cell transfer (ACT) across five different solid tumor types 💉 The process currently used to produce Lifileucel for melanoma proved highly reproducible, as shown by the NucleoCounter® NC-200™. Key findings included: - Comparable manufacturing success rates across drug products - High purity TILs yielded by the Gen 2 processes for all indications - Robust IFN-γ response upon reactivation Want to elevate your processes? Book a NucleoCounter® NC-202™ demo: https://okt.to/7Y36P0 🤝 #ChemoMetec #NucleoCounter #IovanceBiotherapeutics #Cellcounting

[ 🔔 📢 NEW PUBLICATION-WHITE PAPER: Histology Independent Drug Development – Is This the Future for Cancer Drugs?] The Cancer Drug Development Forum (CDDF) is delighted to announce that the White Paper has been developed following its ‘Histology Independent Drug Development – Is This the Future for Cancer Drugs?’ workshop, which took place on 14-15th November 2022, in Amsterdam. The hybrid meeting was set up to explore the current landscape of histology independent drug development, review the current regulatory landscape and propose recommendations for improving the conduct of future trials. 🔔📑 Read the full article published in Cancer Treatment Reviews here: https://lnkd.in/ebgtynQA #Cancer #oncologytrials #HistologyIndependent #Tumour #Biomarkers #DataSharing

As next-generation sequencing becomes a ubiquitous part of routine cancer care, it’s impact in designing and refining drug development remains in flux. Clinical trial design, biomarker identification and cohort analysis have begun to adapt to the changing landscape over the past decade however challenges remain with standardization and federation of data. In this webinar we will explore the only kitted CGP assay submitted to FDA for PMA up to this point, TruSight Oncology 500 (TSO500) from Illumina Available as a research-use-only tool, TSO500 sets the standard for reproducibility across sites, with exceptional accuracy and specificity across a broad range of preserved tissue types. Register here: https://ow.ly/J6Yq50RH7i8

As next-generation sequencing becomes a ubiquitous part of routine cancer care, it’s impact in designing and refining drug development remains in flux. Clinical trial design, biomarker identification and cohort analysis have begun to adapt to the changing landscape over the past decade however challenges remain with standardization and federation of data. In this webinar we will explore the only kitted CGP assay submitted to FDA for PMA up to this point, TruSight Oncology 500 (TSO500) from Illumina Available as a research-use-only tool, TSO500 sets the standard for reproducibility across sites, with exceptional accuracy and specificity across a broad range of preserved tissue types. Register here: https://ow.ly/J6Yq50RH7i8

Visit our AACR 2024 poster with Sanofi to learn about our recent study investigating spatiotemporal tumor immune modulation with different mono- or combined cancer therapeutics. Our research included the use of antibody I/O agents at different time points and drug concentrations that were introduced simultaneously into a tumor with the Kibur NanoNail. Check out the details of this exciting study at the link provided! #AACR2024 #Sanofi #cancerresearch #KiburMedical #NanoNail